EC has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers.
Merck, known as MSD outside of the United States and Canada, announced the European Commission (EC) has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers: 👉 KEYTRUDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the…
